ASCO 2025: Key Highlights in Advanced Lung Cancer
In extensive-stage small cell lung cancer, tarlatamab demonstrated superiority over chemotherapy in the DeLLphi-304 trial, with favorable patient-reported outcomes including improved cough and exertional shortness of breath. Finally, Dr Preeshagul notes how the IMforte study reported promising results for maintenance atezolizumab plus lurbinectedin, with improved progression-free survival and overall survival, making it a potential option pending further risk-benefit discussion.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CBS News
2 minutes ago
- CBS News
11-year-old boy bravely fighting cancer throws first pitch at Fenway Park
The Boston Red Sox celebrated an 11-year-old boy who is bravely fighting cancer. Max Acuto has gone from isolation in the ICU, to roaring applause filling Fenway Park. "There were so many times we were stuck in the house or the hospital because his counts were low, and we couldn't be surrounded by people. I'm just so happy to be here and have him have this experience," said Courtney Acuto, of her son. Max Acuto, throwing the first pitch Tuesday night, felt like a dream come true for the Princeton family living a nightmare. Their 9-year-old was diagnosed with T-cell acute lymphoblastic leukemia in 2023. Now 11, he's been so brave; a source of inspiration for the WPI baseball team, who have become his supporters and friends thanks to Team Impact. "I play a lot of baseball. I've been practicing a lot. It was really cool. Being on that field and how many people there were," Max said. Cheering Max on the mound is a moment of joy for this family after they have endured so much. But the true celebration comes this December when the sixth grader completes two years of grueling treatment. "Two out of three weeks he's getting chemotherapy. With the procedures he has to get, oral chemo at home, going in every Wednesday for treatment in clinic," said his dad Bryan Acuto. "I remember them telling us it was going to be two full years of chemo. I was like how do we even get there? He is so resilient; So easy going, always has a smile. Honestly he got us through our hardest days," Courtney added. After showing such quiet courage through the hard times, these good times... never seemed so good. "It's hard to imagine at the beginning of treatment we'd be here, and getting his strength back. Being able to watch that - the strength and perseverance he's shown has been really wonderful. The strength Max possesses I didn't know existed," Bryan said.
Yahoo
30 minutes ago
- Yahoo
BeautyHealth (SKIN) To Report Earnings Tomorrow: Here Is What To Expect
Skincare company BeautyHealth (NASDAQ:SKIN) will be announcing earnings results this Thursday after the bell. Here's what to look for. BeautyHealth beat analysts' revenue expectations by 8.9% last quarter, reporting revenues of $69.58 million, down 14.5% year on year. It was a very strong quarter for the company, with an impressive beat of analysts' gross margin estimates and a solid beat of analysts' EBITDA estimates. Is BeautyHealth a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting BeautyHealth's revenue to decline 17.5% year on year to $74.74 million, improving from the 22.9% decrease it recorded in the same quarter last year. Adjusted loss is expected to come in at -$0.02 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. BeautyHealth has missed Wall Street's revenue estimates twice over the last two years. Looking at BeautyHealth's peers in the personal care segment, some have already reported their Q2 results, giving us a hint as to what we can expect. USANA delivered year-on-year revenue growth of 10.8%, beating analysts' expectations by 4.7%, and Nature's Sunshine reported revenues up 3.8%, topping estimates by 2.2%. USANA traded up 12.4% following the results while Nature's Sunshine was also up 13.7%. Read our full analysis of USANA's results here and Nature's Sunshine's results here. Investors in the personal care segment have had fairly steady hands going into earnings, with share prices down 1.9% on average over the last month. BeautyHealth is down 25.9% during the same time and is heading into earnings with an average analyst price target of $1.66 (compared to the current share price of $1.63). When a company has more cash than it knows what to do with, buying back its own shares can make a lot of sense–as long as the price is right. Luckily, we've found one, a low-priced stock that is gushing free cash flow AND buying back shares. Click here to claim your Special Free Report on a fallen angel growth story that is already recovering from a setback. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Fox News
32 minutes ago
- Fox News
Woman given months to live beats brain cancer with new cell treatment: 'I feel good'
Pamela Goldberger, a New Jersey grandmother, shares how she overcame her devastating brain cancer diagnosis through a clinical trial for a stem cell treatment.
